Abbott Laboratories (NYSE: ABT) reported Q3 EPS of $1.30, $0.02 better than the analyst estimate of $1.28. Revenue for the quarter came in at $9.77 billion versus the consensus estimate of $9.93 billion.

Abbott Laboratories sees FY2012 EPS of $5.06-5.08, versus prior guidance of $5.00-5.10 and the consensus of $5.06.

For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.

Earnings Guidance Hot Earnings

Raymond James Downgrades Abbott Labs (ABT) to Market PerformOctober 18, 2012 7:51 AM Abbott (ABT) Sees Q4 Sales Growth in Low-Mid Single-Digit RangeOctober 17, 2012 9:45 AM